<?xml version="1.0" encoding="utf-8"?>
<doi_batch xmlns="http://www.crossref.org/schema/4.3.6" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" version="4.3.6" xsi:schemaLocation="http://www.crossref.org/schema/4.3.6 https://www.crossref.org/schemas/crossref4.3.6.xsd">
  <head>
    <doi_batch_id>_1630700478</doi_batch_id>
    <timestamp>1630700478</timestamp>
    <depositor>
      <depositor_name>brea</depositor_name>
      <email_address>akaviani@archbreastcancer.com</email_address>
    </depositor>
    <registrant>Farname Inc</registrant>
  </head>
  <body>
    <journal>
      <journal_metadata>
        <full_title>Archives of Breast Cancer</full_title>
        <abbrev_title>Arch Breast Cancer</abbrev_title>
        <issn media_type="electronic">2383-0433</issn>
      </journal_metadata>
      <journal_issue>
        <publication_date media_type="online">
          <month>01</month>
          <day>28</day>
          <year>2021</year>
        </publication_date>
      </journal_issue>
      <journal_article xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" publication_type="full_text" metadata_distribution_opts="any">
        <titles>
          <title>COX-2 Expression in Carcinoma of the Breast and Surrounding  Non-neoplastic Breast Tissue</title>
        </titles>
        <contributors>
          <person_name contributor_role="author" sequence="first" language="en">
            <given_name>Namita</given_name>
            <surname>Bhutani</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Shilpi</given_name>
            <surname>Moga</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Pooja</given_name>
            <surname>Poswal</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Bhanu</given_name>
            <surname>Sharma</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Sunil</given_name>
            <surname>Arora</surname>
          </person_name>
          <person_name contributor_role="author" sequence="additional" language="en">
            <given_name>Sham </given_name>
            <surname>Singla</surname>
          </person_name>
        </contributors>
        <jats:abstract xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1">
          <jats:p>Background: Breast carcinoma is the most common malignant tumor and leading cause of cancer related death in women worldwide. Apart from traditional markers, estrogen receptor, progesterone receptor and Her-2neu, which are important for prognostication and staging purposes, a novel marker cyclooxygenase-2 (COX-2) is being studied extensively. We intend to study the spectrum of COX-2 expression in normal breast tissue, ductal carcinoma in situ (DCIS) adjacent to invasive cancer, and in invasive cancer and compare COX-2 expression with histological prognostic parameters and hormone receptor status.Methods: The present study is a prospective study that was conducted in the department of Pathology, SGT Medical College and Hospital, Gurugram (2019-2020). Fifty patients, aged between 21 and 70, suffering from primary breast cancer constituted the study group. Various histological prognostic parameters were assessed. Immunohistochemical profile of the tumor was assessed. COX-2 score was correlated with various clinicopathologic parameters.Results: Among the total of 50 patients suffering from invasive breast carcinoma, 94 percent (47/50) of cases showed the same COX-2 expression level in normal breast epithelium and corresponding tumor areas and this correlation was statistically significant. The correlation between the level of COX-2 expression in tumor and DCIS was highly significant.Conclusion: Inhibition of COX-2 may represent a potential target for preventing breast cancer oncogenesis and as an adjuvant treatment following surgery to reduce local recurrence.</jats:p>
        </jats:abstract>
        <publication_date media_type="online">
          <month>01</month>
          <day>28</day>
          <year>2021</year>
        </publication_date>
        <pages>
          <first_page>29</first_page>
          <last_page>36</last_page>
        </pages>
        <ai:program xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" name="AccessIndicators">
          <ai:license_ref>http://creativecommons.org/licenses/by-nc/4.0</ai:license_ref>
        </ai:program>
        <doi_data>
          <doi>10.32768/abc.20218129-36</doi>
          <resource>https://www.archbreastcancer.com/index.php/abc/article/view/342</resource>
          <collection property="crawler-based">
            <item crawler="iParadigms">
              <resource>https://www.archbreastcancer.com/index.php/abc/article/download/342/463</resource>
            </item>
          </collection>
          <collection property="text-mining">
            <item>
              <resource mime_type="application/pdf">https://www.archbreastcancer.com/index.php/abc/article/download/342/463</resource>
            </item>
          </collection>
        </doi_data>
      </journal_article>
    </journal>
  </body>
</doi_batch>
